Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Barocas and Penson have offered a helpful new review of racial variation in the patterns and the quality of care offered to prostate cancer patients in the USA. The entire paper is available on line through the UroToday web site.
Filed under: Living with Prostate Cancer, Management | Tagged: care, pattern, quality, race, variation | Leave a Comment »
New data published in the July issue of the British Journal of Urology International suggest the possibility of a connection between a man’s bone mineral density and his risk for prostate cancer, most particularly the more aggressive and dangerous forms of the disease.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: bone mineral content, risk | 2 Comments »
Media reports are stating that a research team at the Jonsson Comprehensive Cancer Center in Los Angeles have identified basal prostate calls as having the potential to become cancerous and therefore lead to the development of clinically identifiable prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: basal, cell, trigger | Leave a Comment »
Natural orifice transluminal endoscopic surgery or NOTES refers to the conduct of minimally invasive surgery through natural orifices (like the mouth or the vagina or the nose).
Filed under: Management, Treatment, Uncategorized | Tagged: minimally invasive, NOTES, radical prosatectomy | Leave a Comment »
A media release from New York University Langone Medical Center, issued yesterday, has announced the initiation of a multi-center, Phase I/II clinical trial of vascular-targeted photodynamic therapy (VTP) in men with localized prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: localized, photosensitizer, vascular-targeted photodynamic therapy, WST11 | 5 Comments »
Traditional forms of hormone therapy for prostate cancer are based on the idea that you reduce testosterone levels as low as you can so as to stop the ability of testosterone and its metabolites (e.g., dihydrotestosterone) to stimulate growth of prostatic tissues — including prostate cancer cells.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, bipolar, castration-resistant, CRPC, therapy | 1 Comment »
As an adjunct to the 12-year outcome data provided in the immediately preceding report come data from Canada that compare actual 5-year brachytherapy outcome data to predicted 5-year surgical outcome data for the same patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, comparison, outcome, surgery | 3 Comments »
The long-term data on outcomes after first-line treatment with brachytherapy for localized prostate cancer are becoming increasingly compelling, and studies have also suggested strongly that quality of life data are better after brachytherapy than after other forms of treatment.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, long-term, outcome, seed implantation | 7 Comments »
There is a good deal of media noise today about a newly published study in Archives of Internal Medicine. The study addresses the “risk profiles and treatment patterns” of US prostate cancer patients diagnosed with a PSA of ≤ 4.0 ng/ml.”
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, low risk, over-treatment, PSA, Treatment | 7 Comments »
According to a media release issued yesterday by the University of North Carolina Lineberger Cancer Center, researchers at this institution have been awarded the first contract we are aware of ”to conduct comparative effectiveness research comparing different management strategies for localized prostate cancer.”
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comparative effectiveness, localized, outcome, quality of life | 4 Comments »
DoD PCRP stands for the Congressionally mandated Department of Defense Prostate Cancer Research Program — and it is the only US government-sponsored initiative that dedicates funding specifically to prostate cancer research. (Similar DoD cancer programs provide dedicated funding for research into breast, lung, colon, and ovarian cancers.)
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: DoD, funding, PCRP, research | 1 Comment »
There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice: Angiogenic effect of a specific statin on prostate cancer development Synergistic impact of calcitriol on cryotherapy Hybrid imaging techniques and prostate cancer GTI-2040 in treatment of CRPC
Filed under: Drugs in development, Management, Risk, Treatment | Tagged: angiogenesis, calcitriol, cryotherapy, GTI-2040, hybrid, imaging, statin, synergy | Leave a Comment »
The conclusion of a meta-analysis of data from 12 prior studies suggests that drinking coffee has no significant impact on risk for prostate cancer. This news will no doubt come as a great relief to the good people at Starbucks!
Filed under: Diagnosis, Risk | Tagged: coffee | Leave a Comment »
Over the past few months, the US Food and Drug Administration (FDA) has issued a slew of letters to companies marketing tests designed to provide consumers with information about their genetic profile and their risks for certain types of disease.
Filed under: Diagnosis, Risk | Tagged: genes, genetics, risk, test | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site